| Literature DB >> 28716891 |
Aravinda M de Silva1, Eva Harris2.
Abstract
Dengue virus (DENV) is the most common arthropod-borne viral disease of humans. Although effective vaccines exist against other flaviviral diseases like yellow fever and Japanese encephalitis, dengue vaccine development is complicated by the presence of four virus serotypes and the possibility of partial immunity enhancing dengue disease severity. Several live attenuated dengue vaccines are being tested in human clinical trials. Initial results are mixed, with variable efficacy depending on DENV serotype and previous DENV exposure. Here, we highlight recent discoveries about the human antibody response to DENV and propose guidelines for advancing development of safe and effective dengue vaccines.Entities:
Mesh:
Substances:
Year: 2018 PMID: 28716891 PMCID: PMC5983190 DOI: 10.1101/cshperspect.a029371
Source DB: PubMed Journal: Cold Spring Harb Perspect Biol ISSN: 1943-0264 Impact factor: 10.005